Cipla shares traded lower after the drugmaker reported a sharp year-on-year decline in December-quarter profit, prompting ...

Jefferies downgraded Syngene to 'underperform' and slashed price target to Rs 480 from Rs 660; JPMorgan downgraded Cipla to ...

In Q3, Cipla's net profit dropped 57 per cent year-on-year (Y-o-Y) to ₹675 crore, as compared to ₹1,570.51 crore a year ago ...

Jan 23 (Reuters) - Cipla, India's third-largest drugmaker by revenue, reported a 57% quarterly profit decline on Friday as ...

Bata India, Indian Hotels, IGL, MGL, Just Dial, Kalyan Jewellers, Jubilant FoodWorks, Oberoi Realty, Mankind Pharma and ...

In light of Cipla's weak Q3 earnings, brokerages including Goldman Sachs, HSBC, and BofA have all cut target price on the ...

Jan 23 (Reuters) - Cipla, India's third-largest drugmaker by revenue, reported a steeper-than-expected 57% fall in quarterly ...

Several brokerages downgraded Cipla following a weaker-than-expected December quarter performance, citing softness in US ...

Drugmakers Sun Pharma, Cipla, Zydus and Graviti Pharmaceuticals are recalling different products in the U.S., most of them over manufacturing issues.

Cipla Ltd (BOM:500087) reports robust growth in key segments despite facing margin pressures and supply disruptions.

Net Sales at Rs 7,074.48 crore in December 2025 up 0.02% from Rs. 7,072.97 crore in December 2024. Quarterly Net Profit at Rs. 675.80 crore in December 2025 down 56.97% from Rs. 1,570.51 crore in ...

Welcome to the Cipla Stock Liveblog, your go-to platform for real-time updates and analysis on a top-performing stock. Stay ahead of the market with our in-depth coverage of Cipla, including: Last ...